About UsWe are a 49 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Peptides, Biosimilars, Injectables and Ophthalmics and Solid Orals. These are manufactured in our cGMP compliant plants located in India. We market our products globally to 57 countries. In the financial year 2009-10, our sales were Rs. 10,211 million. Our Indian business contributed 67% to this and the rest was from export of APIs and Finished Dosages.
In India we are recognized for our leadership in the Oral Anti-Diabetic market where we rank No. 1 by Rx and Value. In the Cardiovascular diseases segment we are No. 1 by Rx and in the top 10 by Value. We also have a significant presence in the areas of Gynaecology, Dermatology, Gastroenterology and General Practice.
Our international business consists of:
* A large portfolio of small molecule APIs. Of the 54 products in our portfolio, 21 APIs are commercially available, with others in various stages of development. Our special skills include production and characterization of polymorphs and particle sizing.
* A portfolio of Finished Dosages. These include immediate release, modified release and products with 'complex' characteristics which are promoted through ANDA filings and Dossiers linked to supply.
Our spend of 7% of sales on R&D ensures that we are able to deliver on our research portfolio. We have over 100,000 sq. ft. of laboratory space with excellent infrastructure. Our research is driven by a team of 250 scientists including 3 doctors, 33 PhDs and 165 post-graduates, many of whom have studied in universities in USA, Europe and Japan. Our intellectual property portfolio consists of 83 patent filings of which 30 have been granted. |
Processing...
